United Therapeutics Corp
Change company Symbol lookup
Select an option...
UTHR United Therapeutics Corp
HGKGY Power Assets Holdings Ltd
ICPT Intercept Pharmaceuticals Inc
KEY KeyCorp
TTWO Take-Two Interactive Software Inc
TOPS Top Ships Inc
BOLT Bolt Biotherapeutics Inc
ACET Adicet Bio Inc
VCNX Vaccinex Inc
DYNT Dynatronics Corp

Health Care : Biotechnology | Mid Cap Value
Company profile

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.

Closing Price
Day's Change
-0.16 (-0.07%)
B/A Size
Day's High
Day's Low
(Above Average)

10-day average volume:



All providers
September 28, 2023
3D Systems (DDD) to Expand VSP Bolus Distribution With Klarity

3D Systems' (DDD) collaboration with Klarity is likely to help it in expanding the distribution of its FDA-approved VSP Bolus solution.(Zacks)

September 22, 2023
United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs

--UThymoKidney(TM) demonstrates normal function during a 61-day study --Human xenotransplant clinical studies could begin in 2025 United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two...(BusinessWire)

September 12, 2023
United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its 2023 Corporate Responsibility and Public Benefit Report covering its 2022 progress toward its public benefit goals and objectives...(BusinessWire)

September 06, 2023
September 01, 2023
United Therapeutics Corporation to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company's business during a fireside chat session at...(BusinessWire)

August 17, 2023
August 02, 2023
United Therapeutics Corporation Reports Second Quarter 2023 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2023. Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared...(BusinessWire)

July 26, 2023
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.(Zacks)

United Therapeutics Corporation to Report Second Quarter 2023 Financial Results Before the Market Opens on Wednesday, August 2, 2023

United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its second quarter 2023 financial results before the market opens on Wednesday, August 2, 2023. United Therapeutics will host a public webcast Wednesday, August 2...(BusinessWire)

July 24, 2023
United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation United Therapeutics brought...(BusinessWire)

May 04, 2023
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.(Zacks)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.